Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

An announcement from Regis Healthcare Ltd. ( ($AU:REG) ) is now available. Regis Healthcare Limited announced the results of its Annual General Mee...

Regis Healthcare Successfully Concludes Annual General Meeting with Key Resolutions Passed

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

In a report released today, RJ Milligan from Raymond James reiterated a Buy rating on Regency Centers, with a price target of $80.00. According to ...

Regency Centers (REG) Gets a Buy from Raymond James

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $725.00. The company’s sha...

BMO Capital Remains a Buy on Regeneron (REGN)

Insiders have been trading these 5 stocks: (($BX)), (($REGN)), (($SCHW)), (($TSE:CLS)) and (($GLW)). Here is a breakdown of their recent trades and...

Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a pivotal Phase ...

Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron, with a price target of $750.00. The company’s ...

Evercore ISI Remains a Buy on Regeneron (REGN)

Evercore ISI analyst Steve Sakwa maintained a Hold rating on Regency Centers yesterday and set a price target of $78.00. The company’s shares close...

Evercore ISI Remains a Hold on Regency Centers (REG)

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals recently complet...

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron today and set a price target of $870.00. The company’s shares opened today at $...

Regeneron (REGN) Gets a Buy from Jefferies

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on CapitaLand Mall (CPAMF – Research Report) and Regen...

Analysts Are Bullish on These Real Estate Stocks: CapitaLand Mall (CPAMF), Regency Centers (REG)

An announcement from Smart Powerr Corp ( ($CREG) ) is now available. On October 23, 2025, Smart Powerr Corp., a Nevada corporation, entered into se...

Smart Powerr Corp Raises $20M in Private Placement

In a report released today, William Pickering from Bernstein maintained a Buy rating on Regeneron, with a price target of $781.00. The company’s sh...

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a critical study t...

Regeneron’s New Phase 3 Study on Mibavademab: A Potential Game-Changer for Generalized Lipodystrophy

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a new clinical stu...

Regeneron Launches New Study on Mibavademab for Monogenic Obesity

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals recently updated its clinical st...

Market Cap	$13.12B	P/E Ratio	15.34
52W High	$78.18	52W Low	$63.44
Div Yield	302.0%	Payout Ratio	497.4%
EPS Growth 3Y	0.0%	52W Position	50.4%
Overall Score	58	Value Score	90
Quality Score	--	Technical Score	27

EPS Current Est	$4.62	EPS Next Est	$4.8
EPS Growth Est	+3.9%	DPS Growth 3Y	2.9%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$70.87	+2.10%	1.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$70.87	+2.1%	1.18M
3
4
5
6

REG

REG

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel